Samuel R Saks Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Samuel R Saks.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Samuel R Saks. Samuel R Saks is Director in PDL BIOPHARMA, INC. ($PDLI) and Director in DEPOMED INC ($DMI) and Chief Development Officer in Protagonist Therapeutics, Inc ($PTGX) and Chief Medical Officer in Protagonist Therapeutics, Inc ($PTGX) and Director in Tonix Pharmaceuticals Holding Corp. ($TNXP) and Chief Development Officer in Auspex Pharmaceuticals, Inc. ($ASPX).
Latest Insider Trading Transactions of Samuel R Saks
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, DMI, ASPX, PDLI, PTGX, TNXP
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 2021 | PTGX | Protagonist Therap ... | Saks Samuel R | Chief Medical Offic ... | Option Exercise | A | 23.57 | 90,000 | 2,121,300 | 90,000 | |
| Feb 26 2021 | PTGX | Protagonist Therap ... | Saks Samuel R | Chief Medical Offic ... | Grant | A | 0.00 | 12,000 | 0 | 14,000 | 2 K to 14 K (+600.00 %) |
| Feb 28 2020 | PTGX | Protagonist Therap ... | Saks Samuel R | Chief Medical Offic ... | Option Exercise | A | 7.80 | 85,000 | 663,000 | 85,000 | |
| Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
| Jun 24 2019 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Option Exercise | A | 3.00 | 126,050 | 378,150 | 126,050 | |
| May 16 2019 | PTGX | Protagonist Therap ... | Saks Samuel R | Chief Medical Offic ... | Option Exercise | A | 10.80 | 45,000 | 486,000 | 45,000 | |
| Mar 04 2019 | PTGX | Protagonist Therap ... | Saks Samuel R | Chief Development O ... | Option Exercise | A | 8.02 | 15,000 | 120,300 | 15,000 | |
| Mar 04 2019 | PTGX | Protagonist Therap ... | Saks Samuel R | Chief Development O ... | Grant | A | 0.00 | 2,500 | 0 | 2,500 | 0 to 2.5 K |
| Jun 13 2018 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 4.25 | 20,000 | 85,000 | 20,000 | |
| Jun 12 2018 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Grant | A | 2.76 | 54,348 | 150,000 | 214,190 | 159.8 K to 214.2 K (+34.00 %) |
| May 31 2018 | PTGX | Protagonist Therap ... | Saks Samuel R | Chief Development O ... | Option Exercise | A | 7.28 | 50,000 | 364,000 | 50,000 | |
| Mar 09 2018 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | M | 0.00 | 650 | 0 | 0 | |
| Mar 09 2018 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | M | 0.00 | 750 | 0 | 0 | |
| Mar 09 2018 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | M | 0.00 | 750 | 0 | 0 | |
| Mar 09 2018 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Buy | M | 0.00 | 600 | 0 | 3,855 | 3.3 K to 3.9 K (+18.43 %) |
| Mar 09 2018 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Buy | M | 0.00 | 750 | 0 | 5,855 | 5.1 K to 5.9 K (+14.69 %) |
| Mar 09 2018 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Buy | M | 0.00 | 750 | 0 | 6,605 | 5.9 K to 6.6 K (+12.81 %) |
| Jun 21 2017 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 4.18 | 20,000 | 83,600 | 20,000 | |
| Jun 12 2017 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Grant | A | 2.47 | 60,729 | 150,001 | 159,842 | 99.1 K to 159.8 K (+61.27 %) |
| Jun 21 2016 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Buy | P | 2.00 | 25,000 | 50,000 | 63,550 | 38.6 K to 63.6 K (+64.85 %) |
| Jun 03 2016 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Grant | A | 3.52 | 71,023 | 250,001 | 99,113 | 28.1 K to 99.1 K (+252.84 %) |
| May 31 2016 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
| May 20 2016 | DMI | DEPOMED INC | Saks Samuel R | Director | Option Exercise | A | 0.00 | 3,131 | 0 | 3,131 | |
| May 20 2016 | DMI | DEPOMED INC | Saks Samuel R | Director | Option Exercise | A | 19.16 | 7,669 | 146,938 | 7,669 | |
| May 13 2016 | DMI | DEPOMED INC | Saks Samuel R | Director | Payment of Exercise | F | 17.52 | 734 | 12,860 | 5,099 | 5.8 K to 5.1 K (-12.58 %) |
| Feb 10 2016 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
| Dec 03 2015 | DMI | DEPOMED INC | Saks Samuel R | Director | Payment of Exercise | F | 19.00 | 966 | 18,354 | 2,897 | 3.9 K to 2.9 K (-25.01 %) |
| Sep 16 2015 | PDLI | PDL BIOPHARMA, INC ... | Saks Samuel R | Director | Grant | A | 5.34 | 28,090 | 150,001 | 28,090 | 0 to 28.1 K |
| Jul 17 2015 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Buy | P | 7.50 | 10,000 | 75,000 | 32,550 | 22.6 K to 32.6 K (+44.35 %) |
| May 13 2015 | DMI | DEPOMED INC | Saks Samuel R | Director | Option Exercise | A | 0.00 | 2,936 | 0 | 2,936 | |
| May 13 2015 | DMI | DEPOMED INC | Saks Samuel R | Director | Option Exercise | A | 20.43 | 7,857 | 160,519 | 7,857 | |
| May 06 2015 | ASPX | Auspex Pharmaceuti ... | Saks Samuel R | Chief Development O ... | Option Exercise | D | 0.00 | 15,000 | 0 | 0 | |
| May 06 2015 | ASPX | Auspex Pharmaceuti ... | Saks Samuel R | Chief Development O ... | Option Exercise | D | 59.66 | 30,000 | 1,789,800 | 0 | |
| May 06 2015 | ASPX | Auspex Pharmaceuti ... | Saks Samuel R | Chief Development O ... | Option Exercise | D | 0.86 | 27,235 | 23,422 | 0 | |
| May 06 2015 | ASPX | Auspex Pharmaceuti ... | Saks Samuel R | Chief Development O ... | Option Exercise | D | 0.86 | 47,777 | 41,088 | 0 | |
| May 06 2015 | ASPX | Auspex Pharmaceuti ... | Saks Samuel R | Chief Development O ... | Option Exercise | D | 0.90 | 7,777 | 6,999 | 0 | |
| May 06 2015 | ASPX | Auspex Pharmaceuti ... | Saks Samuel R | Chief Development O ... | Sell | U | 0.00 | 67,338 | 0 | 0 | 67.3 K to 0 (-100.00 %) |
| Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 0.00 | 6,000 | 0 | 6,000 | |
| Feb 27 2015 | TNXP | Tonix Pharmaceutic ... | Saks Samuel R | Director | Option Exercise | A | 5.95 | 5,000 | 29,750 | 5,000 |
Page: 1